Douglas E. Giordano — Senior Vice President of Worldwide Business Development at Pfizer

Mr. Douglas E. Giordano, also known as Doug, has been President and Treasurer at Medivation, Inc. since September 28, 2016. Mr. Giordano has been Senior Vice President of Worldwide Business Development at Pfizer Inc., since June 2010. Mr. Giordano has been Vice President of Icagen, Inc., since October 27, 2011. He is a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard and Pfizer Helpful Answers programs. Before his US pharmaceuticals operating role, he worked in a mergers and acquisitions role within Pfizer's Medical Technology Group ' playing a key role in Pfizer's acquisitions, technology licensing and divestiture activity within medtech. He served as Vice President of Business Transactions at Pfizer Inc. He served as Vice President of Worldwide Business Development of Pfizer from April 2007 to June 2010 and Vice President of US Planning and Business Development of Pfizer from July 2005 to March 2007. For over two years, he led teams responsible for all Pfizer acquisitions and product licensing transactions including Pfizer's acquisitions of Coley, CovX. Encysive and Serenex and product collaborations announced with Adolor, Avant and Medivation. Before joining Pfizer's Worldwide Business Development group in 2007, he was of member of Pfizer's US leadership team responsible for US strategy and business development. Mr. Giordano serves as Director at ViiV Healthcare Limited. He has been a Director of ICU Medical, Inc. since February 3, 2017. He has been a Director of Medivation, Inc. since September 28, 2016. He has been a Director of Icagen, Inc. since October 27, 2011 and Anacor Pharmaceuticals, Inc. since June 24, 2016. He served as a Director of Zoetis Inc. from July 2012 to June 2013. He served as Director of Encysive Pharmaceuticals Inc. from April 2008 to June 2008. He holds a Bachelor's Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University's Johnson School of Business.